Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Value Of ¹⁸F-FDG PET/CT In Assessment Of Metabolic Response In Esophageal Cancer For Prediction Of Histopathological Response And Survival After Preoperative Chemoradiotherapy.

M. Mysliveček, Č. Neoral, R. Vrba, K. Vomáčková, J. Cincibuch, R. Formánek, P. Koranda, J. Zapletalova
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
AIM To evaluate the ability of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) to predict histopathological response and overall survival (OS) after preoperative neoadjuvant chemoradiotherapy (CRT) in patients with the esophageal carcinoma. METHODS 73 patients with locally advanced esophageal carcinoma were included in the study. All were treated with CRT and 34 subsequently underwent surgical resection of the esophagus. (18)F-FDG PET/CT was carried out prior to (PET/ CT1) and 6 weeks after (PET/CT2) completion of the CRT. RESULTS PET/CT2-determined complete metabolic response (CMR) was achieved in 6 (17.6%) out of 34 operated patients, the metabolic response was incomplete (NCMR) in 28 (82.4%) patients. A histopathological complete response (CR) to CRT was discovered in 7 patients (20.6%). The median OS in operated patients was 17.1 months, 95% CI:12.9-23.3 months. In a group of 39 non-operated patients, CMR after neoadjuvant CRT was achieved in 12 patients (30.8%), while NCMR was found in 28 (82.4%). The median OS was 13.5 months in this group, 95% CI: 4.4-22.7 months. CONCLUSION No statistically significant correlation was found between the (18)F-FDG metabolic response after the neoadjuvant CRT and histopathological response. Presently, the contribution of (18)F-FDG PET/CT as a marker of the potential result of CRT cannot be considered definite. Another study with a larger sample of patients and standardized algorithms for the examining protocols would be necessary for reaching definitive conclusions.
This paper references
10.1200/JCO.2003.04.013
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.
R. Downey (2003)
10.1097/00000421-198602000-00020
Cancer : Principles and Practice of Oncology
V. Devita (1982)
10.1111/j.1442-2050.2007.00732.x
Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
B. M. Smithers (2008)
10.1016/J.IJROBP.2005.03.033
FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
S. Y. Song (2005)
10.1093/ANNONC/MDF081
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
P. Flamen (2002)
10.1038/sj.onc.1207726
International variation
D. Parkin (2004)
10.1200/JCO.2006.06.7801
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
K. Ott (2006)
10.1016/S0016-5085(98)82369-X
The detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer
G. Couper (1998)
10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations
A. Mandard (1994)
10.1016/S0002-9610(02)00932-7
Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer.
H. Kato (2002)
10.1259/BJR.72.858.10560332
Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma.
D. Mcateer (1999)
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial
D. Girling (2002)
10.1016/S0003-4975(99)00974-1
Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.
J. Luketich (1999)
10.1016/J.EJCA.2007.04.001
Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
M. K. Kim (2007)
10.1016/J.EJSO.2004.03.007
Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma.
I. Brink (2004)
10.1097/01.sla.0000208430.07050.61
Predictive Value of 18-Fluoro-Deoxy-Glucose-Positron Emission Tomography (18F-FDG-PET) in the Identification of Responders to Chemoradiation Therapy for the Treatment of Locally Advanced Esophageal Cancer
E. Levine (2006)
10.1200/JCO.2005.23.16_SUPPL.4063
A phase II trial of preoperative one cycle of induction chemotherapy [capecitibine (CAP), CDDP] followed by concurrent chemoradiation (CRT) in patients (pts) with resectable esophageal cancer
Sang Bae Kim (2005)
Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy.
B. Beseth (2000)
10.1093/ANNONC/MDH219
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.
J. Lee (2004)
10.1016/S1470-2045(07)70039-6
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
V. Gebski (2007)
10.1002/(ISSN)1097-0142
Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians
T. G. Freedman (1997)
glucose - positron emission tomography ( 18 F - FDG - PET ) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer
SY Song
10.3322/canjclin.55.1.10
Cancer Statistics, 2005
A. Jemal (2005)
10.1007/BF01249629
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
Pierre Rigo (2005)
10.1056/NEJMOA055531
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
D. Cunningham (2006)
10.1200/JCO.2005.10.192
Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer.
S. Couban (2005)
10.1002/cncr.11660
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
K. Becker (2003)
10.1016/S1470-2045(07)70244-9
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
F. Lordick (2007)
10.1007/BF00052188
Survival of cancer patients in europe—The EUROCARE study
F. Pannelli (2004)
10.1200/JCO.2005.05.017
Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.
A. Berger (2005)
10.1046/J.1365-2168.1998.00963.X
Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer
G. Couper (1998)
10.1200/JCO.2001.19.12.3058
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
W. Weber (2001)
[Cancer of the esophagus].
T. Watamuki (1970)
Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esopha
RJ Cerfolio (2008)
10.1200/JCO.2000.18.18.3202
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
P. Flamen (2000)
10.1016/j.jtcvs.2008.02.016
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
I. Higuchi (2008)
10.1056/NEJM199608153350702
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
T. Walsh (1996)
Cancer of the esophagus
R. BarreraCacicedo (1960)
10.1200/JCO.2005.00.034
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
M. Stahl (2005)
10.1001/ARCHSURG.139.10.1043
Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma.
W. Kneist (2004)
10.1016/J.JTCVS.2004.12.042
The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
R. Cerfolio (2005)
10.1200/JCO.2000.18.4.868
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
E. Heath (2000)
10.1016/S0003-4975(97)00619-X
Improvement in staging of esophageal cancer with the addition of positron emission tomography.
M. Block (1997)
10.1200/JCO.2001.19.2.305
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
S. Urba (2001)
10.1016/J.ATHORACSUR.2004.04.046
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
S. Swisher (2004)
10.1016/J.ATHORACSUR.2007.03.094
Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.
J. Port (2007)
10.2967/jnumed.108.057232
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
B. Krause (2009)
10.1016/S1278-3218(98)89075-6
Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.
J. Bosset (1997)
10.1002/(SICI)1097-0142(19990301)85:5<1026::AID-CNCR3>3.0.CO;2-N
Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy
D. Jones (1999)
A comparison of 18FDG PET and CT in the staging of oesophageal carcinoma
G Cook (1997)
10.1097/00000658-200103000-00002
Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography
B. Brücher (2001)
10.2214/AJR.168.2.9016218
Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.
F. Flanagan (1997)
10.1056/nejmra035010
Esophageal cancer.
P. Enzinger (2003)
International variation. Oncogene 2004;23:6329-40
DM Parkin (2004)



This paper is referenced by
10.1159/000351435
Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting the Early Response to Chemoradiotherapy of Advanced Esophageal Squamous Cell Carcinoma
Shunsuke Imanishi (2013)
Similarities and differences of neoadjuvant therapy among different sites of cancers
Zhai Haoran (2015)
10.2967/jnumed.117.207670
Prognostic Value of Standardized Uptake Ratio in Patients with Trimodality Treatment of Locally Advanced Esophageal Carcinoma
R. Bütof (2019)
F ‐ fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy
P. Zhang ()
10.9738/INTSURG-D-16-00163.1
18F-FAMT-PET is useful for judging clinical complete response in advanced esophageal cancer patients who have received definitive chemoradiotherapy
M. Sohda (2017)
10.1016/j.critrevonc.2016.08.015
Impact of PET/CT on radiation treatment in patients with esophageal cancer: A systematic review.
J. Lu (2016)
10.1159/000443018
Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy
S. Chang (2016)
10.1007/s00268-018-04901-z
Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature
D. M. Voeten (2018)
10.1016/j.ebiom.2019.05.023
Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy
C. Xie (2019)
10.1093/JJCO/HYW132
The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
Lihong Cong (2016)
10.3238/arztebl.2015.0545
The role of PET and PET-CT scanning in assessing response to neoadjuvant therapy in esophageal carcinoma.
M. Schröer-Günther (2015)
10.1155/2015/518281
Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival
K. O’Sullivan (2015)
Expanding the role of positron emission tomography-computed tomography and its utility in the management of oesophageal cancer
Vinod Malik (2018)
10.1002/bjs.9670
Value of CT–PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma
J. A. Elliott (2014)
10.1016/j.jtho.2019.04.004
Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis.
D. J. de Gouw (2019)
Semantic Scholar Logo Some data provided by SemanticScholar